Acute myeloid leukemia type M2a is a type of acute leukemia with a prognosis mainly related to genes, age, and extramedullary infiltration. With poor prognosis-related genes, higher age, and extramedullary infiltration, the prognosis is generally poor. 1. Genes: the presence of genes associated with poor prognosis (e.g. TP53, SRSF2, etc.) is associated with poor prognosis. When there are genes associated with good prognosis (e.g. NPM1, etc.), the prognosis is relatively good. 2. Age: Age ≥60 years, history of myelodysplastic syndrome or myeloproliferative neoplasms have poor prognosis. The prognosis is relatively better in children and adults of younger age. 3. Extramedullary infiltration: If there is an extramedullary infiltration with a high white blood cell count (≥100 x 10^9/L), the prognosis is poor. If the diagnosis of AML M2a is confirmed, it is recommended to receive active and regular treatment under the guidance of a physician in order to achieve a better therapeutic outcome.
Support Us
Discussion
Share your experience, or seek help from fellow patients.
